Press Releases Nanexa AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
0.92 ^SEK	+1.10%		-2.34%	-25.20%

May. 15	Nanexa AB Elects Hanna Tilus as Members of the Board	CI
May. 15	Nanexa AB Receives Approval for NEX-22 Clinical Study	CI

Bulletin from Nanexa’s Annual General Meeting	May. 15	AQ
Nanexa receives approval for NEX-22 clinical study	May. 15	AQ
Nanexa Q1 2024 - Insightful capital markets day	May. 10	AQ
Equity Research \| NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential	May. 10	AQ
Nanexa publishes interim report for January-March 2024	May. 03	AQ
Invitation to comment on Nanexa's Q1 report 2024	Apr. 30	AQ
Nanexa invites to Capital Markets Day on May 7	Apr. 29	AQ
Approval of clinical trial application for NEX-22 study delayed	Apr. 16	AQ
Notice of annual general meeting in Nanexa AB (publ)	Apr. 15	AQ
Nanexa publishes annual report for 2023	Mar. 27	AQ
Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized	Feb. 22	AQ
Equity Research \| NANEXA: Focus on dual GLP-1 opportunities and the partner projects	Feb. 22	AQ
Nanexa publishes year-end report and Q4 report 2023	Feb. 21	AQ
Invitation to presentation of Nanexa's year-end report and Q4 report 2023	Feb. 20	AQ
Equity Research \| NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play	Dec. 21	AQ
Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA	Dec. 20	AQ
Nanexa optimizes business operations through tactical priorities	Dec. 20	AQ
Nanexa changes Certified Adviser to Carnegie Investment Bank AB (publ)	Nov. 30	AQ
Nanexa signs evaluation agreement with a large global pharmaceutical company	Nov. 29	AQ
Nanexa Q3 - Focused approach	Nov. 21	AQ

No results for this search